Revolutionary War at Ft. Ward

Revolutionary War at Ft. Ward

drum, drumming, drummers

Drummers play “Yankee Doodle” for a crowd at the Revolutionary War Reenactment at Fort Ward Museum and Historic Site on February 20, 2011.

On Sunday I went to a Revolutionary War reenactment at Fort Ward. It was like the Civil War reenactment I attended a few weeks ago, but set about 100 years earlier. Though, it didn’t seem like the weapons and medical techniques were all that different.

pam bronson, debbie barlow, katy hayes, helen anderson, revolutionary war

From left to right, Pam Bronson, Debbie Barlow, Katy Hayes and Helen Anderson take a break from answering visitor questions during the skirmish at the Revolutionary Way Reenactment at Fort Ward Museum and Historic Site.

cannon, revolutionary war

Revolutionary War reenactors prepare to fire a cannon while other reenactors fire muskets during the skirmish demonstration at the Revolutionary Way Reenactment at Fort Ward Museum and Historic Site.

william heartland, surgeon, fort ward

William Heartland, portraying a surgeon in the First Virginia Regiment, demonstrates 18th-century medical equipment during the Revolutionary War Reenactment at Fort Ward Museum and Historic Site on February 20, 2011. The event was part of a weekend-long celebration of George Washington’s birthday.

liberty or death

A Revolutionary War reenactor digs through a bag at the Revolutionary Way Reenactment at Fort Ward Museum and Historic Site.

gunpowder, revolutionary war

A Revolutionary War reenactor empeties a hat full of gunpowder cartridges into a storage box during the Revolutionary Way Reenactment at Fort Ward Museum and Historic Site.

Kampung inhabitants need more medical personnel

Kampung inhabitants need more medical personnel

JUBI, 22 February 2011

Kampung inhabitants need more medical personnel

People living in Mosso kampung, district of Muaratami have urged the
Health Service to increase the number of medical personnel available to kampung dwellers because it is very inadequate at present.

‘We need help from the medical service because we are getting complaints every day from patients about the lack of medical facilities,’ said Charle Wetapoa, an official.

He said that the lack of personnel had been a problem for years, with
the result that people living in the kampung are finding it difficult to
get the medical assistance they need. He said that there were only two people working at the clinic in the kampung

He said that they have called on the Health Service in Jayapura to
prioritise medical personnel for Mosso this year , which would help
improve the conditions of the people in the kampung, especially with
regard to their health.

The Mosso kampung is part of the administrative district of Jayapura
Municipality but is located at a great distance from other kampungs in
the same district, meaning that it is very difficult for the people to
get the service they need. There are altogether 45 people living in the
kampung.

[COMMENT: This is happening in a territory like Papua that is providing
revenues for the Indonesian state coffers from the hugely profitable
mining operations of Freeport copper-and-gold mine. TAPOL

Ampio Pharmaceuticals, Inc. Announces Initiation Of Phase 1B Clinical Trial For Its Anti-inflammatory Drug Ampion™

Main Category: Arthritis / Rheumatology
Also Included In: Bones / Orthopedics;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 01 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE)(“Ampio”) announced that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion™. Patients are now being recruited for first dosing in the three arm, placebo controlled, 60 patient trial designed to demonstrate efficacy in the treatment of osteoarthritis of the knee as well as to confirm patient safety and tolerance.

The present “standard of care” treatment for this condition is the injection of a short acting local anesthetic agent combined with a long acting steroid into and around the joint. In the Ampion trial the mitigation of pain and loss of function caused by osteoarthritis will be assessed at intervals from the time of injection. Patients will be evaluated for 72 hours and various parameters will be followed to demonstrate that Ampion™ is well tolerated and provides pain relief through decreased inflammation as well as demonstrated improvement in the range of motion of the knee.

Dr. David Bar-Or, MD, Ampio’s Chief Scientific Officer, noted, “We discovered this molecule in patients with severe head injury who experienced decreased immune/inflammatory function. The molecule is produced in the body from our own serum albumin and is the most abundant protein in human plasma. We realized from our studies in human tissue that this molecule is an integral part of the innate control of inflammation. We know of many molecules made by our body that increase inflammation but of very few that decrease it. We are hopeful that Ampion™, with few or no side effects, will provide real relief for patients suffering from chronic inflammatory conditions,” stated Dr. Bar-Or.

Ampio CEO Don Wingerter noted, “Since Ampion™ is a biologic product made by our bodies, we believe there is the probability of markedly greater safety than steroids or other anti-inflammatory drugs. We anticipate this clinical trial will demonstrate sufficient proof of safety and efficacy to allow longer term studies in which relief may be obtained without prolonged use of steroids, especially when knee replacement is not an option. We are hopeful this drug will provide clinical utility and safety greater than products now selling in the multi-billion dollar market for anti-inflammatories.”

Vaughan Clift, MD, Ampio’s Chief Regulatory Officer added, “We are very grateful to our Australian Principal Investigators, Dr. Peter Lewis and Dr. Andrew Comley, who helped in the design of the trial and approval process and whose leadership has resulted in encouraging support from local General Practitioners who are also identifying and referring patients into this AIK (Ampion in knee) trial. We expect the trial results will form the basis for submissions to various regulatory agencies to conduct Phase II/III studies of the active component in numerous inflammatory conditions. We believe the nature of the compound and its human origin should facilitate a faster regulatory approval path in most countries compared to the traditional new drug therapies.”

More about Zertane™ Phase III Clinical trial Results

On another note, CEO Wingerter added: “Our May 23, 2011 press release relating to the results of our Phase III study for our male sexual dysfunction drug, Zertane™, used for the treatment of premature ejaculation, generated significant inquiries that led us to provide additional information on our website about the medical condition and the trial results in a QA format. Ampio expects to shortly present a web-based conference of the trial results that will include comparisons to published data on the only other PE drug currently marketed in Europe as well as our commercial strategic plan for this product.”

Source: Ampio Pharmaceuticals, Inc



Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Arthritis / Rheumatology headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.

CrystalGenomics Initiates CG100649 Phase 2b Study In Patients With Osteoarthritis

Main Category: Bones / Orthopedics
Also Included In: Arthritis / Rheumatology;  Clinical Trials / Drug Trials;  Pharma Industry / Biotech Industry
Article Date: 01 Jun 2011 – 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  
<!– rate icon rate article




Patient / Public:not yet rated

Healthcare Prof:not yet rated

CrystalGenomics, Inc. (Seoul, Korea) and CG Pharmaceuticals, Inc. (Emeryville, California), a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics’ clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis (OA).

CG100649 is a first-in-class NSAID drug candidate that is a dual inhibitor of COX-2 and carbonic anhydrase (CA). CG100649’s interaction with carbonic anhydrase in red blood cells provides it with a novel “tissue-specific” transport mechanism that is designed to deliver sustained levels of drug to inflamed tissues, while maintaining low systemic exposure. Its unique dual COX-2 and CA binding properties are designed to provide potentially superior safety to cardiovascular, renal, and gastrointestinal tissues compared to traditional NSAIDs or COX-2 inhibitor drugs.

An earlier placebo-controlled Phase 2a efficacy study in hip and knee in 248 OA patients in Europe showed that a 1.2 mg daily dose provided a highly significant efficacy profile vs. the three major OA symptoms of pain, stiffness, and physical disability. Although this was not an active-comparator trial, the efficacy profile of CG100649 appeared to be at least as favorable as other COX-2 drugs. This prompted CrystalGenomics to conduct a supra-threshold Phase 1 Multiple Ascending Dose (MAD) study in healthy subjects last year that showed that higher doses of CG100649 (2, 4, or 8 mg per day) are likely to provide even higher levels of efficacy while maintaining CG100649’s favorable safety profile.

The current Phase 2b study is a double-blind, randomized, multicenter, non-inferiority, repeat dose study of CG100649 versus celecoxib (Celebrex®) in OA patients. This is the first time that the OA efficacy of CG100649 is being tested directly against celecoxib in the same clinical trial. Considering that CG100649 had already shown a high level of efficacy at 1.2 mg per day in its Phase 2a OA study, it is anticipated that doses of 2 mg/day and 4 mg/day in the Phase 2b study should demonstrate that CG100649 is at least comparable (non-inferior) to celecoxib in terms of efficacy. If the initial hypothesis is supported, additional tests will evaluate whether CG100649 produces superior efficacy compared to celecoxib. Biomarker results from two previous clinical pharmacology studies in healthy volunteers suggest that CG100649 may produce efficacy results that are superior to celecoxib in this Phase 2b study.

In this Phase 2b study, only subjects recording average pain scores of 4 to 8 on a 0-10 numerical rating scale will be randomized into the study. Study participants will then receive 28 daily doses of either 2 mg/day or 4 mg/day of CG100649, or 200 mg/day of celecoxib. Anti-arthritic efficacy will be evaluated using the standardized Western Ontario and McMaster Universities (WOMAC) OA Index and the WOMAC subscales that measure pain, stiffness, and physical function.

Source: CrystalGenomics, Inc



Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care
professional. For more information, please read our terms and conditions.

  Follow us on Twitter
news icon  Bones / Orthopedics headlines
email icon  email to a friend
printer icon  printer friendly version
newsletter icon  weekly newsletter
star icon  personalize your news

back to top - icon  back to top


Please note that we publish your name, but we do not publish your email address. It is only used to let
you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

MediLexicon International Ltd Logo

Privacy Policy |
Terms and Conditions


MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.